Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Lilly Abemaciclib Research Grant Opportunity: Submit by Friday, July 10, 2020
Study Proposal Submission-NCCN iEnvision
NCCN Pfizer Axitinib Research Grant Opportunity: Submit by Wednesday, August 12, 2020
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

Seattle Cancer Care Alliance
Seattle, Washington
206.288.SCCA (7222)

Find a clinical trial >

Adult Oncology

Through Seattle Cancer Care Alliance, patients have access to a broad range of oncology services offered by Fred Hutchinson Cancer Research Center and UW Medicine. These services include chemotherapy, radiation therapy, immunotherapy, surgery, and bone marrow/stem cell transplantation. The primary aims of the adult services are to provide optimal patient care and to engage in both clinical and basic research to develop and evaluate new approaches for treating malignant and non-malignant diseases.


Multidisciplinary Teams

All patients are cared for by multidisciplinary teams of physicians with expertise in the management of cancer.

Special Expertise

  • Autoimmune Diseases
  • Bladder Cancer
  • Blood Disorders
  • Bone Marrow/Stem Cell Transplants
  • Brain and Spinal Cord Cancers
  • Breast Cancer in Women and Men
  • Breast Health
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Gastrointestinal Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma/Other Skin Cancers
  • Mesothelioma
  • Myeloma
  • Myelodysplastic Syndrome (MDS)
  • Ovarian Cancer
  • Palliative Care
  • Pancreatic Cancer
  • Pediatric Bone Marrow/Stem Cell Transplants
  • Prostate Cancer
  • Salivary Gland Cancer
  • Sarcoma
  • Stomach Cancer


General Information


General Information Line

206.288.SCCA (7222)

Referring Physician Line

Patient Intake Office - 206.288.SCCA (7222)

Bone Marrow Transplant Information/Clinical Coordinator - 800.804.8824


Seattle, Washington


SCCA has three clinical practice sites located on the campuses of the three partner organizations.

  • A 38-bed pediatric hematology/oncology unit at Seattle Children's
  • Three adult hematology/oncology units totaling 86 beds at University of Washington Medical Center
  • Outpatient services in a seven-story, 210,000 square foot state-of-the-art clinic located on the Fred Hutch campus. The clinic offers a comprehensive array of services including radiology, CT scanning, MRI, mammography, ultrasound, nuclear medicine, a medical laboratory, and a pharmacy. In addition, the facility houses the clinical immunogenetics, cytogenetics, and molecular diagnostics labs.


A housing coordinator is available to assist patient and family members in locating temporary housing while in Seattle . For more information, contact the SCCA Housing Coordinator at 206.288.1078.


Volunteer van drivers provide transportation to and from the Seattle-Tacoma International Airport and Boeing Field. For more information, contact Volunteer Services at 206.288.1075. Free shuttle service is provided between SCCA, Seattle Children's, and University of Washington Medical Center.

Social Support

Social workers assist patients and family members in adjusting to and managing issues surrounding illness. Services available include pre-arrival consultations, advocacy and referral coordination, education, counseling, and support groups. Additional support services are available for child care and sibling schooling for long-term treatment stays, For assistance, call 206.288.1076.

Volunteer Services

Patient and family volunteers are available if desired to offer companionship and practical assistance. Volunteers are matched based on similar interests, professions, spirituality, and cultural background. For more information, call 206.288.1075.

International Patients

An international patient liaison is available to assist patients and family members in accessing services needed at the Alliance and in the Seattle community.


K-12 Educational Services

A kindergarten through twelfth grade educational program, known as the Hutch School , is available to school-aged family members of patients and pediatric patients. Hutch School offers a supportive learning environment as well as educational support and continuity. For more information, call the Hutch School at 206.667.1400.

Home Health Care

Home health care is arranged for adult transplant patients.

Ages Treated

Adults of all ages are treated.

Acceptance Criteria

The patient must meet the inclusion criteria of open protocols or standard treatment plans.

Average Number of Adult Clinical Trials





Bone Marrow and Stem Cell Transplant Program


Fred Hutchinson Cancer Research Center performs approximately 400 hematopoietic stem cell transplants a year, including 50-60 pediatric transplants. Transplantation is available for all types of hematologic malignancies and non-malignant hematologic disorders as well as a number of solid tumors, genetic disorders, and autoimmune diseases. Active protocols exist for transplantation with bone marrow, peripheral blood stem cells, and umbilical cord blood from related as well as unrelated donors. (Umbilical cord blood, normally discarded after the delivery of a newborn, appears to have important qualities that make it good for transplantation and makes the transplanted cells less likely to attack the body of the person getting the transplant.) Fred Hutch performs all types of donor transplants: autologous-self donor, syngeneic-identical twin donor, allogeneic-related donor, allogeneic-unrelated donor, and allogeneic-"mismatched" donor. Also performed are myeloablative and non-myeloablative transplants. We also offer mini-transplants when appropriate, using lower doses of chemotherapy and radiation prior to transplantation.

Long-Term Follow-Up Program

Fred Hutch has the largest long-term follow-up program in the world, following patients long-term after transplantation and providing life-long monitoring and care of patients following a bone marrow or stem cell transplant. These services are provided through Fred Hutch and the Seattle Cancer Care Alliance (SCCA). Fred Hutch physicians and researchers work in partnership with a patient's personal doctor to resolve medical problems and to gather information for research. This information is used to develop improved strategies for preventing and treating long-term effects of transplantation and to educate patients about post-transplant problems.

Clinical and Research Services

Clinical Long-Term Follow-Up (LTFU) services at Seattle Cancer Care Alliance (SCCA) serve patients and their doctors following bone marrow or stem cell transplant. Services include telephone consultation with doctors who are caring for transplant recipients after their return home and discussions about post-transplant problems and concerns with patients and family members.

Two nurses and a nurse practitioner with expertise in LTFU care after transplantation manage telephone inquiries. These individuals meet at regular intervals with a doctor who reviews cases and makes recommendations for management of problems. For some types of problems, local patients may return to SCCA for specialized care, such as treatment for graft vs. host disease (GVHD). Patients receiving allogeneic (donor) transplants are also asked to return to the SCCA at the one-year anniversary of their transplant for special testing to review their progress.

When a patient returns home after a transplant, they become part of the Fred Hutchinson Cancer Research Center 's Long-Term Follow-Up Research Program. This is a life-long program of monitoring that continues for as long as the patient is willing to participate. Patients (and their doctors) are asked to complete a questionnaire at six months after transplant, at one year, and each year thereafter. Collecting data from patients and their doctors, even decades after treatment, allows Fred Hutchresearchers to learn about the long-term effects of transplant. This is most helpful in determining the best course of preventive care or treatment for current as well as future patients. It is extremely important that patients who are not having post-transplant problems participate in this program. Participation ensures that our research is more accurate and informative.

Special Expertise

Seattle Cancer Care Alliance physicians and specialists are among the best in the nation and come from many disciplines-medical oncology, surgical oncology, radiation oncology, pathology, and more. Many of the physicians are involved in research to better understand how disease occurs and translate this information into better and more effective therapies. Below are excerpts of some of the Alliance cancer-care services.


Brain and Spinal Cord Cancers

The mission of the neuro-oncology team is to provide the best possible patient-focused care and state-of-the-art treatment. They have an active research team that works toward developing and identifying clinical research studies, including nation-wide industry-sponsored studies and those from the National Cancer Institute. Each week, a unique group of physicians from UW Medicine and Fred Hutchinson Cancer Research Center meet to discuss neuro-oncology cases and determine the best course of treatment for each patient. Treatment is available for every type of tumor, state-of-the-art rehabilitation services are also available. The Neuro-Oncology Team uses the latest technology to diagnose and treat brain and spinal cord tumors, including Magnetic Resonance Imaging (MRI), MRI Spectroscopy, MRI Perfusion Scans, Functional MRI, Diffusion Tensor Imaging, Intra-operative Computed Tomography (CT) Scanning, Leskell Gamma Knife, LINAC (Linear Accelerator) Radiosurgery, and Clinical Research Studies.

Gastrointestinal cancer

At SCCA, treatment is available for gastrointestinal cancer, including cancer of the stomach, esophagus, intestine, colon, rectum, or anus as well as the liver, bile duct, gall bladder, and ampulla. Doctors at Seattle Cancer Care Alliance are working to develop new and improved treatments for gastrointestinal cancer. The treatment choices offered at SCCA include surgery, chemotherapy, and radiation therapy. Many colorectal cancer patients come to SCCA to gain access to leading-edge treatments, including those available in clinical trials. Also available is the Gastrointestinal Cancer Prevention Program, a personalized approach to cancer risk assessment, screening, and prevention for people who have a high risk of developing most types of gastrointestinal cancer (colon, small intestine, stomach, pancreas, and esophagus).


Our leukemia patients can choose from standard therapy options as well as leading-edge therapies designed from the latest research findings. Many of these therapies involve marrow and stem cell transplantation and adoptive immunotherapy techniques. Fred Hutchinson Cancer Research Center 's Bone Marrow Transplant Program is the core of the Alliance 's transplant services. Working with its SCCA partners, Fred Hutch researchers have focused on the development of more targeted and lower toxicity therapies to treat leukemia, such as techniques using monoclonal antibodies to target high-dose radiotherapy and chemotherapy to sites of malignant disease and mini-transplantation.

Lung Cancer

Seattle Cancer Care Alliance (SCCA) offers leading-edge treatments and innovative therapies for primary and metastatic lung cancer. Our expert team of physicians works with the latest equipment and technologies to provide the highest quality of care available today, from accurately staging disease to having the ability to operate on locally advanced tumors that may be considered "unresectable." Our thoracic surgeons are board-certified with special training in thoracic oncology, including VATS (video-assisted thoracic surgery) for more minimally-invasive lung surgery.


Patients with lymphoma have access to a wide array of treatment options, ranging from standard treatment plans to clinical trials, including marrow and stem cell transplantation and more targeted therapies using monoclonal antibodies, immunotoxins, and radioimmunoconjugates. Another treatment approach is a tandem transplant where a patient first is treated with an autologous stem cell transplant followed by lower-dose chemotherapy and an allogeneic transplant.


Multiple Myeloma

Patients gain entry into some of the most sophisticated therapies available for multiple myeloma, including new drug therapies, chemotherapy, radiation therapies, marrow and stem cell transplantation, or more targeted therapies using radioactive isotopes. Patients also have access to a weekly clinic for special consultation and treatment with the team of physicians specializing in treating myeloma.


Myelodysplastic Disorder (MDS)

Patients are seen by a team of physicians who are working to identify the best approaches to treating patients with myelodysplastic disorders. Patients have access to a weekly clinic staffed by the team. Hemopiotic cell transplantation is still the most effective treatment available for many patients with MDS, but other treatment options exist. Our physicians aim to progressively identify more narrowly defined subgroups of patients with a substantially higher chance of responding to a particular therapy.



Patients are treated by physicians who are part of one of the largest and most active sarcoma programs in the United States . These sarcoma services are a major treatment program offered through University of Washington Medical Center at SCCA. It is composed of two multidisciplinary clinics, for adults and pediatric patients. The clinics see nearly 600 new patients each year. At the clinic, patients have access to leading-edge therapies and treatments for the disease, including bone transplants. In addition to standard treatment options, current efforts are focusing on new drug strategies to treat these very difficult cancers.


Thyroid Cancer and other Endocrine Tumors

The Endocrine Neoplasia Clinic focuses on diagnosing and treating thyroid cancer, pheochromocytoma, adrenal tumors, paraganlionomas, parathyroid tumors, and endocrine-secreting pancreatic tumors. The Endocrine Neoplasia Clinic has advanced nuclear medicine techniques and participates in investigational clinical chemotherapy trials for those with advanced or poorly responsive disease. Clinic appointments for consultations and long-term follow-up are available at both facilities. Thyroid scans are available at both facilities. Nuclear medicine consultation is provided at SCCA. Surgeries are performed at UWMC. Radioiodine therapy is performed at UWMC.


Gynecologic Cancer

Women with a gynecological cancer are seen at the SCCA Women's Center, located at the SCCA clinic. SCCA has a comprehensive range of gynecologic oncology services for patients diagnosed with cervical, endometrial, ovarian, and other gynecological cancers. The SCCA sees about 450 new patients each year. A team of physicians, nurses, radiation oncologists, and pathologists who are experts in gynecologic cancers cares for all patients. The physicians are board certified in obstetrics and gynecological oncology, and ­not only do surgery but also administer chemotherapy and work very closely with the radiation oncologists in planning radiation treatment.

Breast Cancer

Women with breast cancer are also seen at the Women's Center at SCCA . Physicians at SCCA are well-known for their multidisciplinary approach to evaluating and treating breast cancer and for collaborating with each other and the patient to develop the best possible treatment plan. Services are individualized for each patient, combining treatment with quality of life, comfort, and resource issues for breast cancer patients. Physicians in the breast cancer group are taking a lead in the development of new therapies for treating breast cancer, including studying new drugs that may benefit patients who are on standard treatment and whose cancer recurs, as well as evaluating high-dose consolidation programs. Others are working on immunotherapy and genetic susceptibility to cancer and other common diseases.


At SCCA, patients have access to the latest therapies and treatments available for melanoma. As with other disease services at SCCA, there is a specialized melanoma clinic open for patients to receive focused care. Nurses and doctors who specialize in melanoma staff the clinic. This team meets regularly to discuss each patient case and treatment options. The team includes two of the Northwest's leading melanoma surgeons, both known for their innovative approach to treating melanoma. Also on the team is a nationally recognized expert in the field of dermatopathology, with particular expertise in the pathological diagnosis of melanoma and in the evaluation and treatment of patients with unusual or atypical moles, as well as oncologists who provide expert care in the administration of chemotherapy and immunotherapy for melanoma. Another physician specializes in the study and treatment of Merkel Cell Carcinoma (MCC), a rare and aggressive type of skin cancer.

Cancer Prevention and Screening Programs

Breast and Ovarian Cancer Prevention Program (BOCPP)

Women determined to be at high risk of developing breast and/or ovarian cancers are referred to the Breast and Ovarian Cancer Prevention Program (BOCPP) at Seattle Cancer Care Alliance (SCCA). This multi-disciplinary program works with high-risk women to individually design a management program for prevention and early detection of cancer. The team of providers includes a genetic counselor, medical oncologist, nutritionist, psychologist, oncology nurse practitioner, and gynecologic oncologist. Patients interested in genetic counseling and testing for cancer predisposition genes are first seen in the Cancer Genetics Clinic in the Division of Medical Genetics at University of Washington Medical Center. To schedule an appointment, patients can call 206.288.6990.



Gastrointestinal Cancer Prevention Program (GICPP)

Individuals at high risk to develop gastrointestinal cancers are referred to the Gastrointestinal Cancer Prevention Program (GICPP) at the Seattle Cancer Care Alliance (SCCA). This multi-disciplinary program works with high risk patients to individually design a cancer screening and prevention plan. The team of providers includes gastroenterologists, each specializing in different hereditary GI cancers, a gynecological oncologist, a genetic counselor, and a nutritionist. Patients interested in genetic counseling and testing for the cancer predisposition genes that have not already gotten testing may be seen first in the Cancer Genetics Clinic in the Division of Medical Genetics of University of Washington Medical Center. Call 206.288.7222 to schedule an appointment.

Cancer Prevention Clinic

The Seattle Cancer Care Alliance (SCCA) and the Fred Hutchinson Cancer Research Center (FHCRC) have established a Cancer Prevention Clinic (CPC) to help meet these organizations' goals to reduce suffering and death due to cancer. The CPC complements the comprehensive cancer center's treatment and research missions by advancing the field of early detection and prevention for all malignancies. The Cancer Prevention Clinic offers the latest medical and scientific knowledge available in combination with the most advanced surveillance and diagnostic methods. The clinic is available to anyone concerned about his or her risk of cancer.

Each clinic patient receives a comprehensive evaluation from our team of physicians trained and certified in cancer prevention and other prevention specialists, including dietitians and physical therapists. Our team works together to develop a personalized cancer risk assessment and reduction program for each client. For additional information call 206.288.7222 or go to www.seattlecca.org/patientsandfamilies/CPC.

Survivorship Program

Patients who have survived cancer and are not in active cancer treatment are referred to the Survivorship Program at the Seattle Cancer Care Alliance (SCCA). As part of the Survivorship Program, patients are given a thorough screening and health evaluation by our medical staff, professionals who have dedicated themselves to learning about and dealing with survivorship issues. Cancer survivors leave with a Survivorship Care Plan that lists all of their therapy and medical information that is pertinent to their diagnosis and any possible late effects. This Survivorship Care Plan has recommendations for the patient and their healthcare provider to keep them as healthy and as informed as possible in the future. Cancer survivors may receive information on nutrition, exercise, or counseling to help optimize their health in the years following their cancer treatment.

The Survivorship Care Plan includes a detailed summary of all diagnostic testing and treatments, as well as available evidence-based standards of care. Copies are provided to the cancer survivor's medical oncologist and primary care physician. For additional information, call 866.543.4272 or 206.667.2814, or e-mail the staff at survivor@fhcrc.org. www.seattlecca.org/patientsandfamilies/Survivorship/.


Statistics - Adult

Percent of adults treated in calendar year 2006


Age Range




50 and older

Number of Cases





Percent Treated







Adult Oncology Program, Calendar Year 2006


No. of Inpatient Beds

No. of Admissions

Average Length of Stay (days)

No. of New Outpatients

Total Outpatient Visits

No. of Bone Marrow Transplants

No. of Oncologists